13F Pro13F Pro

SEC Form 4 reporting owner

Maraganore John

Maraganore John has filed 15 Form 4 transactions reported between January 29, 2026 and October 22, 2026, as a reporting owner of Rapport Therapeutics, Inc., Director of CITY THERAPEUTICS, INC., Director of TAKEDA PHARMACEUTICAL CO LTD, a reporting owner of Kymera Therapeutics, Inc., a reporting owner of Beam Therapeutics Inc. and a reporting owner of Hemab Therapeutics Holdings, Inc..

Name as filed: MARAGANORE JOHN

Follow Maraganore John and get an alert on every new Form 4

Maraganore John holds 2.1M shares of CTY, worth $43.8M.

As of their Oct 15, 2026 Form 4 (filed Oct 19, 2026) · the filing on SEC EDGAR · 1.5M direct, 637,014 indirect · valued at the Oct 26, 2026 close of $20.79

Maraganore John holds 24,200 shares of TAK, worth $494K.

As of their Jul 1, 2026 Form 4 (filed Jul 6, 2026) · the filing on SEC EDGAR · valued at the Oct 26, 2026 close of $20.43

Maraganore John holds 9,411 shares of RAPP, worth $238K, 0.02% of the company.

As of their Oct 22, 2026 Form 4 (filed Oct 22, 2026) · the filing on SEC EDGAR · valued at the Oct 26, 2026 close of $25.33 · 48.0M shares outstanding on Aug 3, 2026

Open-market buys, 24 mo
$249K
2 lines
Open-market sales, 24 mo
None
reported
Companies
6
with Form 4 filings
Latest transaction
Oct 22, 2026
transaction date

Roles and reported holdings

  • RAPPRapport Therapeutics, Inc.
    Jun 10, 2026 – Oct 22, 2026

    Reporting owner

    By John M. Maraganore Revocable Trust9,411 sh

    As of Oct 22, 2026 · Form 4

    24 months: $249K bought

  • CTYCITY THERAPEUTICS, INC.
    Oct 15, 2026 – Oct 19, 2026

    Director

    Held directly1,470,692 sh
    By John M. Maraganore 2021 Irrevocable Trust318,507 sh
    By Christine Maraganore 2021 Irrevocable Trust318,507 sh

    Also reports 22,649 Stock Option (Right to Buy), not counted as shares.

    As of Oct 15, 2026 · Form 4

  • TAKTAKEDA PHARMACEUTICAL CO LTD
    Jul 1, 2026 – Jul 10, 2026

    Director

    Held directly24,200 sh

    By class: 13,800 American Depositary Shares, 10,400 Ordinary Shares.

    Also reports 1,319 Tax Obligation Award, not counted as shares.

    As of Jul 1, 2026 · Form 4

  • KYMRKymera Therapeutics, Inc.
    Jun 24, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • BEAMBeam Therapeutics Inc.
    Jun 3, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • COAGHemab Therapeutics Holdings, Inc.
    Jan 29, 2026 – May 4, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

How their buys did since

2 open-market purchases against today’s price: -4.9% on average, -4.2% weighted by dollars spent.

DatePaidReturn
Oct 22, 2026RAPP$26.92-5.9%now $25.33
Oct 22, 2026RAPP$26.38-4.0%now $25.33

Each purchase at the price on its Form 4, against the latest trade or close, adjusted for stock splits. Past returns say nothing about future ones.

Transaction history

All 15 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Oct 22, 2026RAPPOpen-market purchaseCode P · indirect1,172$32K@ $26.92Form 4
Oct 22, 2026RAPPOpen-market purchaseCode P · indirect8,239$217K@ $26.38Form 4
Oct 19, 2026CTYDirectorConversion of derivativeCode C · direct56,095—Form 4
Oct 19, 2026CTYDirectorConversion of derivativeCode C · direct500,000—Form 4
Oct 19, 2026CTYDirectorConversion of derivativeCode C · direct610,759—Form 4
Oct 15, 2026CTYDirectorGrant or awardCode A · direct22,649—Form 4
Jul 10, 2026TAKDirectorDisposition to issuerCode D · direct1,152$5.7M@ $4931.20Form 4
Jul 1, 2026TAKDirectorGrant or awardCode A · direct1,319—Form 4
Jul 1, 2026TAKDirectorGrant or awardCode A · direct3,800—Form 4
Jun 24, 2026KYMRGrant or awardCode A · direct6,068—Form 4
Jun 10, 2026RAPPGrant or awardCode A · direct15,200—Form 4
Jun 3, 2026BEAMGrant or awardCode A · direct19,676—Form 4
May 4, 2026COAGConversion of derivativeCode C · direct817—Form 4
May 4, 2026COAGConversion of derivativeCode C · direct17,974—Form 4
Jan 29, 2026COAGGrant or awardCode A · direct107,338—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares each ownership line is left at by the person’s latest Form 4, 4/A or 5: held directly, and through each trust or entity named on the filing. A second class of common stock that converts into the listed one counts as shares; options and restricted stock units are listed but not counted. Value uses the latest trade or close, and the share of the company uses the latest shares-outstanding count the company reported. Where a filing has not yet been read line by line, the figure comes from the latest direct and indirect lines that traded and is shown as “at least”.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.